University Of Maryland, Baltimore

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1807-01-01

Employees: 7.3K

Market Cap: -

Website: http://www.umaryland.edu

Clinical Trials

Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder

Phase 2

Withdrawn

Conditions: Opioid-use Disorder

Interventions: Drug: ANS-6637
Drug: Placebo oral tablet

First Posted Date: 2019-11-19

Last Posted Date: 2021-01-28

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT04169360

Worksite Wellness Within Long-term Care Facilities

Not Applicable

Completed

Conditions: Lifestyle Risk Reduction
Worksite Health Promotion
Cardiovascular Diseases
Occupational Stress
Healthcare Workers

Interventions: Behavioral: Education only control
Behavioral: WHHIP PLUS

First Posted Date: 2019-11-18

Last Posted Date: 2024-11-26

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 159

Registration Number: NCT04166643

Locations: 🇺🇸
Edenwald Senior Living, Towson, Maryland, United States
🇺🇸
Sunrise of Pikesville, Pikesville, Maryland, United States
🇺🇸
Sunrise Of Severna Park, Severna Park, Maryland, United States

and more 3 locations

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

Completed

Conditions: Rejection Acute Renal
Transplant;Failure,Kidney
Rejection Acute Pancreas
Transplant; Failure, Pancreas

Interventions: Diagnostic Test: dd-cfDNA Blood Test

First Posted Date: 2019-11-18

Last Posted Date: 2024-11-27

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 140

Registration Number: NCT04166149

Locations: 🇺🇸
UW Health University Hospital, Madison, Wisconsin, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

Hepatitis B Vaccine in Seniors

Early Phase 1

Completed

Conditions: Hepatitis B Vaccination

Interventions: Biological: Intramuscular injection of Recombivax-HB
Biological: Subcutaneous fat injection of Recombivax-HB

First Posted Date: 2019-11-14

Last Posted Date: 2019-11-14

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 52

Registration Number: NCT04162223

Locations: 🇺🇸
University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma

Interventions: Drug: Bavituximab
Drug: Pembrolizumab

First Posted Date: 2019-11-05

Last Posted Date: 2023-09-05

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 7

Registration Number: NCT04150900

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

Ceftaroline Pharmacokinetics in Continuous Renal Replacement Therapy

Phase 4

Completed

Conditions: Infection During Renal Replacement Therapy
Critically Ill

Interventions: Other: Ceftaroline levels in CRRT

First Posted Date: 2019-11-05

Last Posted Date: 2021-03-18

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 4

Registration Number: NCT04152694

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

Exercise Plus Duloxetine for Knee Osteoarthritis

Phase 2

Recruiting

Conditions: Depression
Knee Osteoarthritis

Interventions: Behavioral: Aerobic exercise
Drug: Duloxetine

First Posted Date: 2019-10-01

Last Posted Date: 2024-11-26

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 30

Registration Number: NCT04111627

Locations: 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2

Recruiting

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: galeterone
Drug: Gemcitabine

First Posted Date: 2019-09-20

Last Posted Date: 2024-06-03

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 58

Registration Number: NCT04098081

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

Phase 2

Completed

Conditions: Shigella

Interventions: Biological: SF2a-TT15 Shigella Vaccine
Other: Placebo
Biological: S. flexneri 2a strain 2457T Challenge Agent

First Posted Date: 2019-09-04

Last Posted Date: 2024-05-20

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 58

Registration Number: NCT04078022

Locations: 🇺🇸
University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

Developing and Testing a Brief Intervention for Problem Gambling in Credit Counseling

Not Applicable

Completed

Conditions: Gambling Problem

Interventions: Behavioral: Text messages

First Posted Date: 2019-08-22

Last Posted Date: 2024-04-10

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 45

Registration Number: NCT04064749

Locations: 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy